Lía
Lía Arribas Referencias bibliográficas • 1. Diagnosis of abnormal uterine bleeding in reproductive-aged women. Practice Bulletin N° 128. American College of Obstetrician and Gynecologist. Obstet Gynecol 2012; 120:197. • 2. Munro MG, Critchley HOD, Fraser IS. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertil Steril 2011; 95: 2204-8. • 3. Mei-An Middelkoop, Emma E Don, Wouter J K Hehenkamp, Nicole J Polman, Arjan W Griffioen, Judith A F Huirne. Angiogenesis in abnormal uterine bleeding: a narrative review. Hum Reprod Update 2023 Jul 5;29(4):457-485. • 4. Goyal BK, Gaur I, Sharma S, Saha A, Das NK. Transvaginal sonography versus hysteroscopy in evaluation of abnormal uterine bleeding. Med J Armed Forces India. 2015; 71:120-5. • 5. Diponible en https://www.nice.org.uk/ guidance/ng88 . Accedido en abril 2024. • 6. Rosen A, VenturaChan W, Matelski J, Walsh C, Murj. Medical treatment of uterine arteriovenous malformation:a systematic review and meta-analysis. Fertil Steril 2021 Oct;116(4):1107-1116. • 7. Disponible en https://www.fasgo.org.ar/ images/CONSENSO_SUA_FASGO_2022.pdf . Accedido en abril 2024. • 8. Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;9(9). • 9. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996; 313: 579 – 82. • 10. Fraser I, McCarron G, Markham R, Robinson M, Smyth E. Long-term treatment of menorrhagia with mefenamic acid. Obstet Gynecol 1983; 61: 109 – 12. • 11. Gleeson NC, Buggy F, Sheppard BL, Bonnar J . The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994; 73: 274 – 7. • 12. Bryant-Smith AC, Lethaby A, Farquhar C, Hickey M. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2018, Issue 4. Art. No.: CD000249. • 13. Lukes A, Moore K, Muse K, Gersten J Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010 Oct;116(4):865-875. • 4. Bofill Rodriguez M, Lethaby A, Low C, Cameron IT. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2019, Issue 8. • 15. Goshtasebi A, Moukhah S, Gandevani SB. Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Arch of Gynecol and Obstet 2013;288(5):1055-60. • 16. Munro M, Mainor N, Basu R, Brisinger M, Barreda L. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2006 Oct;108(4):924-9. • 17. Ammerman SR, Nelson A. A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: a pilot study. Am J Obstet Gynecol. 2013;208(6):499 e1–5. • 18. Combined hormonal contraceptives for heavy menstrual bleeding Cochrane review 11 Feb 2019. • 19. Qiu J, Cheng J, Wang Q, Hua J. Levonogestrel-releasing intrauterine system versus medical therapy for menorrhagia: a systematic review and meta-analysis. Medical Science Monitor 2014; 20:1700-13. • 20. Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged WomenNumber 557 (Reaffirmed 2020). Disponible en https://www.acog.org/ clinical/clinical-guidance/committee-opinion/ articles/2013/04/management-of-acute-abnormal-uterine-bleeding-in-nonpregnant-reproductive-aged-women. Accedido en abril 2024. • 21. James A, Kouides P y col. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol 2011 Oct;158(2):124-34. • 22. Organización Mundial de la Salud (2014). Criterios médicos de elegibilidad para el uso de anticonceptivos, quinta edición 2015: resumen ejecutivo, 5a ed. Organización Mundial de la Salud. Disponible en https://apps.who.int/iris/handle/10665/205016. Accedido en mayo 2022. • 23. Fraser IS, Römer T, Parke S, Zeun S, Mellinger U, Machlitt A et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum Reprod. 2011; 26: 2698-708. • 24. Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol. 2011; 117: 777-87. • 25. Kadir RA, Lukes AS, Kouides PA, Fernandez H, Goudemand J, Management of excessive menstrual bleeding in women with hemostatic disorders, Fertil Steril 2005;84:1352, 2005. • 26. Al-Hendy A, Lukes AS, Poindexter AN III, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021;384(7):630–42. • 27. Schlaff WD, et al., Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. N Engl J Med, 2020; 382(4): 328–340. • 28. Simon JA, et al., Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Obstet Gynecol, 2020; 135(6): 1313–1326. 14 // EDITORIAL SCIENS
